These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7713161)

  • 1. The corticosterone-enhancing effects of the 5-HT1A receptor antagonist, (S)-UH301, are not mediated by the 5-HT1A receptor.
    Groenink L; Van der Gugten J; Mos J; Maes RA; Olivier B
    Eur J Pharmacol; 1995 Jan; 272(2-3):177-83. PubMed ID: 7713161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (S)-UH301, a silent 5-HT1A receptor antagonist, enhances plasma corticosterone levels in the rat.
    Groenink L; van der Gugten J; Mos J; Maes RA; Olivier B
    Life Sci; 1994; 55(5):PL99-103. PubMed ID: 8035646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminative stimulus properties of flesinoxan: effects of enantiomers, (S)-UH301 and WAY-100635.
    Gommans J; Hijzen TH; Maes RA; Mos J; Olivier B
    Eur J Pharmacol; 1995 Sep; 284(1-2):135-40. PubMed ID: 8549617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm.
    Millan MJ; Rivet JM; Gobert A; Canton H; Veiga S; Bervoets K
    J Pharmacol Exp Ther; 1994 Apr; 269(1):121-31. PubMed ID: 7909555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons.
    Mos J; Van Hest A; Van Drimmelen M; Herremans AH; Olivier B
    Eur J Pharmacol; 1997 May; 325(2-3):145-53. PubMed ID: 9163561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors.
    Millan MJ; Rivet JM; Canton H; Lejeune F; Bervoets K; Brocco M; Gobert A; Lefebvre de Ladonchamps B; Le Marouille-Girardon S; Verriele L
    J Pharmacol Exp Ther; 1992 Aug; 262(2):451-63. PubMed ID: 1323650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and pharmacology of the enantiomers of UH301: opposing interactions with 5-HT1A receptors.
    Hillver SE; Björk L; Höök BB; Cortizo L; Nordvall G; Johansson AM; Ertan A; Csöregh I; Johansson L; Lewander T; Hacksell U
    Chirality; 1996; 8(8):531-44. PubMed ID: 9025253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The behavioural, but not the hypothermic or corticosterone, response to 8-hydroxy-2-(DI-n-propylamino)-tetralin, is antagonized by NAN-190 in the rat.
    Przegaliński E; Ismaiel AM; Chojnacka-Wójcik E; Budziszewska B; Tatarczyńska E; Błaszczyńska E
    Neuropharmacology; 1990 Jun; 29(6):521-6. PubMed ID: 2143565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
    Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
    J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin.
    Schreiber R; Brocco M; Lefèbvre de Ladonchamps B; Monneyron S; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):822-31. PubMed ID: 7473172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the cardiovascular effects of the 5-HT1A receptor agonist flesinoxan with that of 8-OH-DPAT in the rat.
    Dreteler GH; Wouters W; Saxena PR
    Eur J Pharmacol; 1990 May; 180(2-3):339-49. PubMed ID: 2142096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin.
    Lucot JB
    Eur J Pharmacol; 1994 Feb; 253(1-2):53-60. PubMed ID: 8013549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of (+)WAY 100135 to behavioral, hypothermic and corticosterone effects induced by 8-OH-DPAT.
    Przegaliński E; Filip M; Budziszewska B; Chojnacka-Wójcik E
    Pol J Pharmacol; 1994; 46(1-2):21-7. PubMed ID: 7981767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors.
    Przegaliński E; Filip M; Bijak M; Wedzony K; Budziszewska B; Tokarski K; Maćkowiak M; Fijał K
    Pol J Pharmacol; 1996; 48(1):13-22. PubMed ID: 9112623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement and depression of spinal reflexes by 8-hydroxy-2-(di-n-propylamino)tetralin in the decerebrated and spinalized rabbit: involvement of 5-HT1A- and non-5-HT1A-receptors.
    Clarke RW; Ogilvie J; Houghton AK
    Br J Pharmacol; 1997 Oct; 122(4):631-8. PubMed ID: 9375958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist.
    Caicoya AG; Beneytez ME; Delgado M; Manzanares J; López-Rodríguez ML; Benhamu B; Morcillo MJ; Pozo MA; Rubia FJ; Fuentes JA
    Pharmacology; 2001 May; 62(4):234-42. PubMed ID: 11360001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion.
    Vicentic A; Li Q; Battaglia G; Van de Kar LD
    Eur J Pharmacol; 1998 Apr; 346(2-3):261-6. PubMed ID: 9652368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 5-HT1A receptor ligands in a modified Geller-Seifter conflict model in the rat.
    King CM; Gommans J; Joordens RJ; Hijzen TH; Maes RA; Olivier B
    Eur J Pharmacol; 1997 May; 325(2-3):121-8. PubMed ID: 9163558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
    Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of 5-HT1A receptor agonists, 5-HT1A receptor antagonists and their interaction on the fear-potentiated startle response.
    Joordens RJ; Hijzen TH; Olivier B
    Psychopharmacology (Berl); 1998 Oct; 139(4):383-90. PubMed ID: 9809859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.